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ABSTRACT

ARTICLE HISTORY

Acute intermittent porphyria (AIP) is a rare autosomal dominant hepatic porphyria due to
deficiency of hydroxymethylbilane synthase (HMBS), also known as porphobilinogen deaminase leading to accumulation of porphyrin precursors. However, gene defect alone is usually
not sufficient to cause an acute attack, and many extrinsic factors play a role. Diagnostic tests
are defined, but clinical suspicion is often delayed as symptoms mimic other common conditions. We report a case of a 18-year-old male with severe, persistent, and generalized abdominal
pain along with marked hyponatremia, with subsequent development of altered mentation
needing intensive care. He improved after infusion of intravenous dextrose. AIP can mimic
many common surgical and medical conditions such as appendicitis, cholecystitis, pancreatitis,
etc., and may lead to extensive diagnostics or surgical intervention if missed. Diagnosis of AIP
requires high clinical suspicion. It should be considered in a patient with recurrent abdominal
symptoms, intractable hyponatremia, along with neurological manifestations. Early diagnosis
and treatment can prevent recurrent episodes and can potentially be lifesaving.
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1. Introduction
Acute intermittent porphyria (AIP) is an inherited
metabolic disease with a prevalence of symptomatic
disease in 1–2 per 100 000 [1,2]. It is an autosomal
dominant hepatic porphyria characterized by a partial
deficiency of hydroxymethylbilane synthase (HMBS),
also known as porphobilinogen deaminase, an
enzyme involved in heme biosynthesis [1,3].
Deficiency of HMBS results in accumulation of
upstream products like delta-aminolevulinic acid
(ALA) and porphobilinogen (PBG). The accumulation of these products is amplified by certain medications, alcohol, infections, low caloric intake, or
hormonal imbalances during menstrual cycle and
pregnancy [1]. Although the deficient enzyme and
accumulated metabolites are easily detectable, diagnosis is often unsuspected because it is rare and can
mimic many other common conditions [4]. Here we
present a case of 18-year-old male with recurrent
attacks of undiagnosed abdominal pain.

2. Case story
An 18-year-old Nepali male presented to the emergency department (ED) with severe, persistent and
generalized abdominal pain for five days. At times,
the pain was severe enough to require multiple doses
of morphine. He also complained of severe,
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intermittent cramping pain in all of his limbs. In
addition to that, he had a 10-day history of pain at
the tip of the penis along with burning micturition.
The patient had similar episodes of acute pain at
three instances in the past, at the ages of 10, 13, and
17 years. Each time, he was hospitalized with no clear
diagnosis to explain his pain. He, however, could
temporally relate those episodes to fasting and inadequate caloric intake. Treatment consisted of repeated
high doses of analgesics. He had no known history of
other medical conditions. He denied use of alcohol or
any recreational drugs. He had no family history of
similar symptomatology.
At presentation, he was hypertensive (160/
110 mmHg), tachypneic (20 breaths/min) and tachycardic (105/min) but afebrile. He was anxious and
was clutching his abdomen. Abdomen was nontender and without guarding or rigidity. No organomegaly was noted. Extremities were not swollen or
tender. There was no motor weakness. On examination of skin there was no blistering, scarring, or
erythema. Genital exam was noncontributory (no
urethral discharge or ulcers).
Diagnostic lab tests were significant for a sodium
level of 106 mEq/L. He was admitted to the intensive
care unit and hypertonic saline was started for treatment of hyponatremia. Urinalysis revealed 10–12
white blood cells per high power field. Ceftriaxone
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was initiated empirically pending culture and sensitivities. Renal and liver function tests were normal.
An abdominal-pelvic computed tomography (CT)
with intravenous contrast did not reveal any potential
cause of his pain. He received multiple high doses of
analgesics without much relief, up to 5 mg morphine
every four hours. He was persistently hypertensive
with repeat blood pressure measurements of 166/
106 mmHg and 160/100 mmHg the next day. He
was started on propranolol for high blood pressure
and tachycardia.
On the following day, he developed altered mentation in the form of fluctuating levels of orientation,
agitation, irritability, confusion, and visual hallucination (seeing animals) in the ICU. These neuropsychiatric manifestations were not reported in prior
attacks. Lumbar puncture done to rule out meningoencephalitis was normal. Head computed tomography (CT) and magnetic resonance imaging (MRI)
were both normal for acute or chronic changes.
Alprazolam was started for anxiety, and chlorpromazine was initiated for hallucination and psychotic
features. Sodium level remained low at 112 mEq/L
even with hypertonic saline treatment.
At this point, acute intermittent porphyria (AIP)
was suspected and urine was sent for porphobilinogen (PBG) and delta-aminolevulinic acid (ALA).
Urine from this sample was noticed to be cola colored
in the lab. The results of urine PBG and ALA results
came back positive - about 20 times elevated (PBG:
90 mg/24 hours and ALA 68 mg/24 hours; normal
levels: PBG: 4 mg/24 hours; ALA: 0–7 mg/24 hours).
Diagnosis of acute porphyria (attack) was made. The
patient was treated with glucose loading of 10% dextrose followed by maintenance. Intravenous hematin
was not used due to unavailability and prohibitive
costs.
Three weeks later, the patient was discharged in
good condition and counselled to avoid fasting,
stress, alcohol, and smoking, and to take an adequate
carbohydrate containing diet. He was also given a list
of drugs to avoid and was advised to wear a medical
alert bracelet notifying that he was a porphyria
patient.

3. Discussion
Even though AIP is an autosomal dominant (AD)
condition, our patient did not have a positive family
history. Almost 90% of patients who inherit this disorder remain asymptomatic for lifetime [5]. This
could be explained by the fact that the gene responsible for AIP has an incomplete penetrance so that
the disease often exists in a latent form (i.e., without
clinical or biochemical manifestations) and family
history may not be imminent [6]. The onset of symptoms usually occurs in adolescence, with females
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being more affected than males [7]. However, our
patient was an adolescent male, with an onset of
symptoms since childhood. The attack of acute porphyria in our patient was probably precipitated by
urinary tract infection. Infection is attributable to
precipitation of acute attack in as high as 29% cases
[8]. His three prior episodes were supposedly triggered by fasting. Fasting and inadequate carbohydrate
intake have been shown to precipitate acute porphyria attack in as many as 12% of cases [8].
Elevated PBG (precursor of porphyrin) in urine is
highly sensitive and specific for acute (attack of)
porphyrias (AIP, hereditary coproporphyria, and variegate porphyria). In an appropriate clinical scenario
(e.g., unexplained abdominal pain and vomiting)
qualitative positive PBG urine screen is enough to
initiate treatment without confirming the type.
However, a much better test is to measure the 24hour or even spot urine total PBG. The cornerstone
of management of acute attack of porphyria includes
intravenous hemin along with avoidance of contraindicated drugs and other precipitants, and administration of high dose opiates for pain management
[9,10]. However, hemin is not available and the cost
of procurement is very high in developing nations
like Nepal [11]. Our patient received only IV glucose
in addition to symptomatic management. For diagnosing specific type of acute porphyria, plasma and
stool samples should preferably be collected before
initiating the therapy. Confirmatory tests for AIP are
plasma and stool porphyrins which are usually normal and plasma fluorescence emission spectroscopy
may demonstrate an emission peak at 620 nm. Unlike
other types of acute porphyrias, AIP does not have
cutaneous manifestations [9,10].
Even though genetic testing is considered as the
‘gold standard’ for diagnosis and screening in
families, it could not be performed in our patient
due to similar financial and logistic reasons as above.
Early clinical recognition is crucial for patients
with acute neurovisceral attacks. The diagnosis is
often delayed by many years and has been reported
to be as long as a mean of 15 years [12]. Our patient
was diagnosed at least 10 years after his first clinical
attack. The invaluable clues to correct diagnosis are
gastrointestinal symptoms (acute abdominal pain in
85–90% of attacks), severe intractable hyponatremia
and orange colored urine on exposure to light, in
association with neurologic symptoms [13,14], and
all of these were present in our patient.
Neurological manifestations are probably due to
the neurotoxic effects of porphyrin precursors, ALA
being the most significant. Abdominal pain is a sign
of autonomic neuropathy, due to splanchnic dysfunction such as intestinal dilatation or spasm [15].
In AIP, pathophysiology of hyponatremia is only
partly understood and can be associated with the
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syndrome of inappropriate antidiuretic hormone
secretion, also contributed to by gastrointestinal or
renal sodium loss [13]. In contrast to cutaneous porphyrias, AIP patients are not photosensitive due to
absence of porphyrin accumulation [16].

4. Conclusion
AIP is a mimic of many common surgical and medical conditions like appendicitis, cholecystitis, pancreatitis etc., and may result in extensive diagnostics
or surgical intervention if missed. Diagnosis of AIP
requires high clinical suspicion. It should be considered in a patient with recurrent abdominal symptoms, intractable hyponatremia, along with
neurological manifestations. Early diagnosis can prevent recurrent episodes and can be potentially
lifesaving.
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